Prasad Rejects Moderna Flu Vaccine Despite FDA Staff Approval

Bassyonni

Published: February 11, 2026 4:26 PM ET

Prasad Rejects Moderna Flu Vaccine Despite FDA Staff Approval

The Food and Drug Administration (FDA) faces significant scrutiny regarding vaccine approvals. Recently, Vinay Prasad, a senior official at the FDA, rejected Moderna’s application for a new flu vaccine. This decision comes despite the agency’s reviewers being prepared to move forward with the evaluation.

Details of the Rejection

Insiders revealed that the decision to deny Moderna’s application was unexpected. David Kaslow, who leads the FDA’s vaccine division, had written a comprehensive memo advocating for the review process to begin. Prasad’s refusal to consider this application highlights a growing trend within the FDA.

Increased Scrutiny on Vaccines

This rejection is part of a broader shift towards more rigorous evaluation of vaccines under Prasad’s leadership. Reports indicate that skepticism concerning vaccines is becoming more prevalent within the agency, influenced by prominent figures such as Robert F. Kennedy Jr.

Control Over Vaccine Oversight

Prasad, alongside another official, Tracy Beth Høeg, has taken significant steps in modifying the oversight of vaccine surveillance. This includes assuming control that was previously held by career scientists within the FDA.

Implications of the Decision

The ramifications of this decision are significant. It raises questions about the future of vaccine approvals at the FDA, particularly in relation to public confidence in vaccines. The rejection signals a potential shift in how the agency will evaluate vaccine safety and efficacy moving forward.

Official: Vinay Prasad, FDA Senior Official
Vaccine: Moderna’s New Influenza Vaccine
Key Support: David Kaslow, Head of Vaccine Office
Health Secretary: Robert F. Kennedy Jr.
Other Official: Tracy Beth Høeg

The ongoing developments at the FDA will be closely monitored as stakeholders assess their impact on public health and vaccine trust. The tension between regulatory oversight and vaccine advocacy remains a crucial issue in the current health landscape.